# MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)

> **NCT00420420** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 144 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** MK0249
- **DRUG:** Comparator: Placebo (unspecified)

## Key facts

- **NCT ID:** NCT00420420
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 144 (ACTUAL)
- **Last updated:** 2015-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00420420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00420420, "MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00420420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*